Psychosocial and pharmacologic interventions for disruptive behavior in children and adolescents
Epstein R, Fonnesbeck C, Williamson E, Kuhn T, Lindegren ML, Rizzone K, Krishnaswami S, Sathe N, Ficzere CH, Ness GL, Wright GW, Raj M, Potter S, McPheeters M
Record ID 32015001089
English
Authors' objectives:
We systematically reviewed evidence on psychosocial and/or pharmacologic treatment for children with disruptive behavior disorders.
Authors' recommendations:
Qualitative and quantitative analyses generally suggest that psychosocial interventions for children with disruptive behavior disorders that include a parent component, either alone or in combination with other components, are likely to be more effective at reducing disruptive child behaviors than interventions that include only a child component or control conditions. Small studies of antipsychotics and stimulants report positive effects in the very short term. The most commonly reported outcomes are parent-reported outcomes. Long-term and functional outcomes were not consistently reported. There was variability in the duration of longterm followup and functional outcomes reported.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.effectivehealthcare.ahrq.gov/ehc/products/555/2133/disruptive-behavior-disorder-report-151019.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Child
- Adolescent
- Attention Deficit and Disruptive Behavior Disorders
- Psychological Techniques
- Pharmacologic Actions
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.